AgingResearch.NewsJoin free

Composite cardiovascular outcome (all-cause death, CVD death, myocardial infarction, or stroke)

There is 1 paper on composite cardiovascular outcome (all-cause death, CVD death, myocardial infarction, or stroke) in aging research: 1 observational study in people.

Disease

1 paper studies it3 findings

See all 1 papers on composite cardiovascular outcome (all-cause death, CVD death, myocardial infarction, or stroke)

“elevated suPAR (>3 ng/mL) was associated with a 75% higher risk of the composite outcome (aHR 1.75; 95% CI 1.44–2.26)”
Soluble Urokinase Plasminogen Activator Receptor (suPAR), Lipoprotein(a), and Cardiovascular Outcomes in the Multi-Ethnic Study of Atherosclerosis (MESA)AHA Scientific Sessions 2025 abstract2025doi:10.1161/circ.152.suppl_3.4370425
  • Humans1

Associations

3

suPAR

upin humans1

1 study

  1. suPAR predicts composite cardiovascular outcome (all-cause death, CVD death, myocardial infarction, or stroke) in humans (compared with Lp(a) for discrimination).

    “suPAR showed superior risk discrimination performance compared to Lp(a)”

    Humanscompared with Lp(a) for discriminationn = 4,357

    Soluble Urokinase Plasminogen Activator Receptor (suPAR), Lipoprotein(a), and Cardiovascular Outcomes in the Multi-Ethnic Study of Atherosclerosis (MESA)

    AHA Scientific Sessions 2025 abstract

More on suPAR

Lipoprotein

upin humans1

1 study

  1. Lipoprotein is linked with a higher risk of composite cardiovascular outcome (all-cause death, CVD death, myocardial infarction, or stroke) in humans (fully adjusted Cox models; mutually adjusted for suPAR) (aHR 1.50 (95% CI 1.06–2.13)).

    “High Lp(a) (>70 mg/dL) was also associated with increased risk, though of lower magnitude compared to suPAR (aHR 1.50; 95% CI 1.06–2.13).”

    Humansfully adjusted Cox models; mutually adjusted for suPAR>70 mg/dLn = 4,357

    Soluble Urokinase Plasminogen Activator Receptor (suPAR), Lipoprotein(a), and Cardiovascular Outcomes in the Multi-Ethnic Study of Atherosclerosis (MESA)

    AHA Scientific Sessions 2025 abstract

More on Lipoprotein

Supar

upin humans1

1 study

  1. Supar is linked with a higher risk of composite cardiovascular outcome (all-cause death, CVD death, myocardial infarction, or stroke) in humans (fully adjusted Cox models; mutually adjusted for Lp(a)) (aHR 1.75 (95% CI 1.44–2.26)).

    “elevated suPAR (>3 ng/mL) was associated with a 75% higher risk of the composite outcome (aHR 1.75; 95% CI 1.44–2.26)”

    Humansfully adjusted Cox models; mutually adjusted for Lp(a)>3 ng/mLn = 4,357

    Soluble Urokinase Plasminogen Activator Receptor (suPAR), Lipoprotein(a), and Cardiovascular Outcomes in the Multi-Ethnic Study of Atherosclerosis (MESA)

    AHA Scientific Sessions 2025 abstract

More on Supar

Latest

Related